LRMR (Larimar Pharma) Net earnings per share (EPS TTM)

Larimar Therapeutics focuses on developing protein-based therapies for hereditary pathologies in collaboration with specialized funds. This price chart illustrates the EPS dynamics, which currently stands at -27.10. The business relies on an extensive distribution network to mitigate supply chain disruption risks. However, the lack of sales and dependence on FDA verdicts leave the company vulnerable until the completion of clinical trials for ataxia treatments.
LRMR (Larimar Therapeutics Inc): analytical breakdowns and indicator data

Larimar Therapeutics (LRMR) focuses on developing an innovative replacement protein to combat Friedreich's ataxia. Analyzing the EPS dynamics over the last 12 months YoY allows for tracking the rate of change in net income per share. This indicator calculates the percentage deviation of the current rolling profit total from the same period last year. The steady ascent of the line confirms the effectiveness of the therapy's commercialization, thereby reducing investment risks.